You are here

iPSC-based Treatments for Sensorineural Hearing Loss

Sensorineural hearing loss represents the world's most common sensory deficit, affecting nearly 470 million people. Human induced pluripotent stem cells (iPSCs) can differentiate into otic neurosensory cell derivatives, thereby facilitating the study of disease mechanisms, bioengineering, and stem cell‐based cell replacement therapies either as individual cell types or as three-dimensional organoid cultures. Researchers from the Azel Zine lab (LBN University of Montpellier, France) highlight the significant achievements and challenges associated with iPSC‐based otic cell modeling as a human preclinical platform to understand pathogenesis and identify novel therapies. For all the details, see STEM CELLS now!